Novartis India Ltd Faces Bearish Momentum Amid Technical Indicator Shifts

Technical Trend Overview and Price Movement

As of 29 Jan 2026, Novartis India Ltd’s share price closed at ₹782.95, down 2.22% from the previous close of ₹800.75. The stock traded within a range of ₹780.10 to ₹823.50 during the day, remaining closer to its 52-week low of ₹744.95 than its high of ₹1,099.90. This price action reflects a weakening momentum, consistent with the broader technical downgrade from mildly bearish to bearish.

The daily moving averages have turned bearish, signalling that short-term price trends are under pressure. This is a critical development, as moving averages often serve as dynamic support and resistance levels. The bearish crossover suggests that sellers are gaining control, potentially leading to further downside if the trend persists.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD remains mildly bullish, indicating some underlying positive momentum in the medium term. However, the monthly MACD has turned bearish, signalling that the longer-term trend is weakening. This divergence between weekly and monthly MACD readings suggests that while short-term rallies may occur, the dominant trend remains negative.

Complementing this, the Know Sure Thing (KST) indicator aligns with the MACD’s signals: mildly bullish on the weekly chart but bearish on the monthly. This reinforces the notion that momentum is faltering over the longer horizon, despite intermittent short-term strength.

RSI and Bollinger Bands Analysis

The Relative Strength Index (RSI) currently offers no clear signal on either the weekly or monthly charts, hovering in a neutral zone. This lack of directional RSI momentum suggests that the stock is neither overbought nor oversold, leaving room for further price movement in either direction.

Bollinger Bands, which measure volatility and potential price extremes, are signalling bearishness on the weekly timeframe and mildly bearish conditions monthly. The stock price has been testing the lower bands recently, indicating increased selling pressure and the possibility of continued downward movement if support levels fail to hold.

Volume and Dow Theory Insights

Volume-based indicators such as On-Balance Volume (OBV) have not provided definitive signals recently, leaving volume trends ambiguous. However, Dow Theory assessments reveal a mildly bullish stance on the weekly scale but a mildly bearish outlook monthly. This again highlights the tension between short-term optimism and longer-term caution among market participants.

Comparative Performance and Market Context

Novartis India’s recent returns have lagged behind the broader Sensex benchmark, particularly over longer timeframes. Year-to-date, the stock has gained a modest 0.51%, outperforming the Sensex’s decline of 3.37%. However, over the past year, Novartis India has declined by 12.23%, while the Sensex has advanced 8.49%. This underperformance extends over three and five-year periods, with the stock returning 26.10% and 20.82% respectively, compared to the Sensex’s 38.79% and 75.67% gains.

Over a decade, the stock has essentially stagnated with a -0.55% return, starkly contrasting the Sensex’s remarkable 236.52% growth. These figures underscore the challenges Novartis India faces in delivering sustained shareholder value relative to the broader market.

Mojo Score and Rating Update

MarketsMOJO has recently downgraded Novartis India Ltd’s Mojo Grade from Sell to Strong Sell as of 18 Aug 2025, reflecting deteriorating technical and fundamental conditions. The current Mojo Score stands at 26.0, signalling significant caution for investors. The Market Cap Grade remains low at 3, indicating limited market capitalisation strength relative to peers.

This downgrade aligns with the bearish technical trend and the stock’s underwhelming price momentum, reinforcing the need for investors to reassess their positions carefully.

Outlook and Investor Considerations

Given the prevailing bearish technical indicators, including daily moving averages and monthly MACD, investors should approach Novartis India with caution. The neutral RSI and mixed weekly signals suggest potential for short-term rallies, but the dominant monthly bearishness warns of sustained downward pressure.

Risk-averse investors may prefer to monitor for a confirmed technical reversal or improved fundamental catalysts before committing fresh capital. Conversely, those with a higher risk tolerance might consider tactical trades around support levels near ₹745, but with strict stop-loss discipline.

Sector and Industry Context

Within the Pharmaceuticals & Biotechnology sector, Novartis India’s technical deterioration contrasts with some peers that have maintained stronger momentum and more favourable technical profiles. The sector remains sensitive to regulatory developments, patent expiries, and innovation cycles, which can significantly influence stock performance.

Investors should weigh Novartis India’s current technical weakness against sector trends and company-specific fundamentals, including pipeline progress and earnings outlook, before making allocation decisions.

Summary

In summary, Novartis India Ltd is currently navigating a challenging technical environment marked by a shift to bearish momentum across key indicators. The downgrade to a Strong Sell rating by MarketsMOJO reflects these headwinds, compounded by underperformance relative to the Sensex over multiple timeframes. While short-term technical signals offer some mild bullish hints, the prevailing monthly bearishness and daily moving average trends suggest caution.

Investors should closely monitor technical developments and fundamental news flow, considering alternative investment opportunities within the sector or broader market to optimise portfolio outcomes.

Unlock special upgrade rates for a limited period. Start Saving Now →